Status:
TERMINATED
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this research is to evaluate response to systemic therapy, including anti-angiogenesis therapy and/or immune-based therapies via 18F-DCFPyL prostate-specific membrane antigen ...
Detailed Description
Response of systemic therapy, including anti-angiogenesis therapy and/or immune-based therapies will be quantified using PSMA-based PET imaging using a novel agent,18F-DCFPyL, as a non-invasive imagin...
Eligibility Criteria
Inclusion
- Patients diagnosed with locally advanced (\>/=cT3) or metastatic clear cell RCC as proven by biopsy.
- Adults, 18 years of age or older.
- Surgical candidates who have clinical indication for nephrectomy and standard-of-care biopsy of metastatic disease followed by possible standard of care systemic anti-angiogenesis based treatment regimen
- Have consented to participate in the University of Wisconsin Carbone Cancer Center Biobank.
Exclusion
- Patients who have received prior RCC systemic therapies
- Prior history of prostate cancer
- Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
- Unable to lie flat during or tolerate PET/CT
- Serum creatinine \> 2 times the upper limit of normal
Key Trial Info
Start Date :
December 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03387514
Start Date
December 8 2018
End Date
June 29 2021
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States, 53705